Assay Report. Phosphodiesterase (PDE) Inhibitor Assays Enzymatic Study of Compounds from Client

Transcription

1 Assay Report Phosphodiesterase (PDE) Inhibitor Assays Enzymatic Study of Compounds from Client Page 1 of 36 Client_PDE _Year Month Day 1

2 Client_PDE_Year Month Day PDE Inhibitor Assays Study Sponsor: Client Attention: Address: Study Director: Testing Facility: Henry Zhu, Ph.D. BPS Bioscience Inc. 42 Cornerstone Court West, Ste. B USA Study Period: Report Version: 1 Report Date: Month Day, Year Page 2 of 36 Client_PDE _Year Month Day 2

3 Study Director Scientist Date Henry Zhu, Ph.D. President Date Page 3 of 36 Client_PDE _Year Month Day 3

4 CONTENTS PHOSPHODIESTERASE (PDE) INHIBITOR ASSAYS... 1 ENZYMATIC STUDY OF COMPOUNDS FROM CLIENT... 1 PDE INHIBITOR ASSAYS... 2 STUDY DIRECTOR PURPOSE OF THE STUDY MATERIALS AND METHODS MATERIALS COMPOUNDS EXPERIMENTAL CONDITIONS Enzymes and Substrates Assay Conditions Data Analysis ASSAY RESULTS SUMMARY OF THE INHIBITORY EFFECTS OF THE COMPOUNDS ON INDIVIDUAL PDE ACTIVITIES RESULTS OF THE EFFECTS OF THE COMPOUNDS ON INDIVIDUAL PDE ACTIVITY PDE1A Bay PDE1B Bay PDE1C Bay PDE2A Bay PDE3A Cilostamide PDE3B Cilostamide PDE4A1A Rolipram PDE4A4B Rolipram PDE4A Rolipram PDE4B Rolipram PDE4B Rolipram PDE4C Rolipram PDE4D Rolipram PDE4D Rolipram Page 4 of 36 Client_PDE _Year Month Day 4

5 PDE4D Rolipram PDE5A Sildenafil Citrate PDE6C Sildenafil Citrate PDE7A BRL PDE7B Dipyridamole PDE8A Dipyridamole PDE9A Bay PDEA Papaverine PDEA Papaverine PDE11A Dipyridamole QUALITY ASSURANCE STATEMENT Page 5 of 36 Client_PDE _Year Month Day 5

6 1. Purpose of the Study The purpose of the study is to determine the effects of compounds from Client on the enzymatic activities of recombinant human PDE1A1, PDE1B, PDE1C, PDE2A1, PDE3A, PDE3B, PDE4A1A, PDE4A4B, PDE4A, PDE4B1, PDE4B2, PDE4C1, PDE4D2, PDE4D3, PDE4D7, PDE5A1, PDE6C, PDE7A1, PDE7B, PDE8A1, PDE9A2, PDEA1, PDEA2, and PDE11A4 using an in vitro enzymatic assay. Page 6 of 36 Client_PDE _Year Month Day 6

7 2. Materials and Methods 2.1 Materials Bay-75 is purchased from Cayman Chemicals (Ann Arbor, MI, Item Number 11135). Cilostamide is purchased from Axxora (San Diego, CA, Catalog number BML-PD125). Rolipram is purchased from A.G. Scientific (San Diego, CA, Product Number R-12). Sildenafil Citrate is purchased from Axxora (San Diego, CA, Catalog number LKT- S3313). BRL-481 is purchased from Enzo Life Sciences, (Farmingdale, NY, Catalog number BRL-PD-1). Dipyridamole is purchased from Axxora (San Diego, CA, Catalog number BML-EI127). Bay is purchased from Sigma-Aldrich (St. Louis, MO, Catalog number B3561). Papaverine is purchased from Axxora (San Diego, CA, Catalog number ALX-2-1). PDE Assay Buffer (BPS Catalog number 393). PDE Binding Agent (BPS Catalog number 3). PDE Binding Agent Diluent (camp) (BPS Catalog number 391). PDE Binding Agent Diluent (cgmp) (BPS Catalog number 392). 2.2 Compounds The test compounds are supplied by Client. Compound I.D. Compound Supplied Stock Concentration Dissolving Solvent Test Range (μm) Intermediate Dilution Bay-75* Powder mm DMSO Cilostamide* Powder mm DMSO Rolipram* Powder mm DMSO Sildenafil Citrate* Powder mm DMSO BRL-481* Powder mm DMSO Dipyridamole* Powder mm DMSO.1 for PDE1.1.1 for PDE2A.1 for PDE3.1 for PDE4.1 1 for PDE5A.1 for PDE6C.1 for PDE7A.1 for PDE7B and PDE8A % DMSO in PDE Assay Buffer % DMSO in PDE Assay Buffer % DMSO in PDE Assay Buffer % DMSO in PDE Assay Buffer % DMSO in PDE Assay Buffer % DMSO in PDE Assay Buffer Page 7 of 36 Client_PDE _Year Month Day 7

8 Bay * Powder mm DMSO Papaverine* Powder mm DMSO *Reference compounds..1 for PDE11.1 for PDE9A.1 for PDE % DMSO in PDE Assay Buffer % DMSO in PDE Assay Buffer 2.3 Experimental Conditions Enzymes and Substrates Assay Catalog # Enzyme Lot # Enzyme Used (ng) / Reaction Substrate PDE1A nm FAM-cAMP PDE1B nm FAM-cAMP PDE1C nm FAM-cAMP PDE2A nm FAM-cAMP PDE3A 1612-G.5 nm FAM-cAMP PDE3B GC2.6 nm FAM-cAMP PDE4A1A 1415-G1.1 nm FAM-cAMP PDE-4A4B nm FAM-cAMP PDE-4A GC.128 nm FAM-cAMP PDE4B nm FAM-cAMP PDE4B G1.25 nm FAM-cAMP PDE4C nm FAM-cAMP PDE4D GC.5 nm FAM-cAMP PDE4D nm FAM-cAMP PDE4D nm FAM-cAMP PDE5A G.2 nm FAM-cGMP PDE6C nm FAM-cGMP PDE7A nm FAM-cAMP PDE7B nm FAM-cAMP PDE8A nm FAM-cAMP PDE9A nm FAM-cGMP PDEA G.22 nm FAM-cAMP PDEA2 17-G1.16 nm FAM-cAMP PDE11A G1.18 nm FAM-cAMP Page 8 of 36 Client_PDE _Year Month Day 8

9 2.3.1 Assay Conditions The serial dilution of the compounds was first performed in % DMSO with the highest concentration at mm. Each intermediate compound dilution (in % DMSO) will then get directly diluted x fold into assay buffer for % DMSO and 5µl of the dilution was added to a µl reaction so that the final concentration of DMSO is 1% in all of reactions. The enzymatic reactions were conducted at room temperature for minutes in a µl mixture containing PDE assay buffer, nm FAM-cAMP or nm FAM-cGMP, a PDE enzyme (Table 2.3.1) and the test compound (Section 2.2). After the enzymatic reaction, µl of a binding solution (1: dilution of the binding agent with the binding agent diluent) was added to each reaction and the reaction was performed at room temperature for minutes. Fluorescence intensity was measured at an excitation of 485 nm and an emission of 528 nm using a Tecan Infinite M microplate reader Data Analysis PDE activity assays were performed in duplicate at each concentration. Fluorescence intensity is converted to fluorescence polarization using the Tecan Magellan6 software. The fluorescence polarization data were analyzed using the computer software, Graphpad Prism. The fluorescence polarization (FP t ) in absence of the compound in each data set was defined as % activity. In the absence of PDE and the compound, the value of fluorescent polarization (FP b ) in each data set was defined as % activity. The percent activity in the presence of the compound was calculated according to the following equation: % activity = (FP-FP b )/(FP t -FP b ) %, where FP= the fluorescence polarization in the presence of the compound. The values of % activity versus a series of compound concentrations were then plotted using non-linear regression analysis of Sigmoidal dose-response curve generated with the equation Y=B+(T-B)/1+ ((LogEC-X) Hill Slope), where Y=percent activity, B=minimum percent activity, T=maximum percent activity, X= logarithm of compound and Hill Slope=slope factor or Hill coefficient. The IC value was determined by the concentration causing a half-maximal percent activity. Page 9 of 36 Client_PDE_Year Month Day 9

10 3. Assay Results 3.1. Summary of the Inhibitory Effects of the Compounds on Individual PDE Activities The IC of the compounds against PDEs are summarized on Table 3.1. If the IC is higher than XμM, the percentage inhibition of the compound at XμM is calculated. Table 3.1 Inhibitory Effects of the Compounds on PDE Activities Enzymes IC (μm) or Percentage Inhibition Bay -75 Cilostamide Rolipram Sildenafil Citrate BRL-481 Dipyridamole Bay Papaverine PDE1A1.11 PDE1B.35 PDE1C.43 PDE2A1.69 PDE3A.17 PDE3B.83 PDE4A1A.18 PDE4A4B.14 PDE4A.16 PDE4B1.12 PDE4B2.11 PDE4C1.24 PDE4D2.12 PDE4D3.11 Page of 36 Client_PDE_Year Month Day

11 PDE4D7.12 PDE5A1.46 PDE6C.12 PDE7A1 2.1 PDE7B 4.7 PDE8A1 7.7 PDE9A2.21 PDEA1.95 PDEA2.64 PDE11A4.45 Page 11 of 36 Client_PDE_Year Month Day 11

12 3.2. Results of the Effects of the Compounds on Individual PDE Activity PDE1A Bay -75 Table Data for the Effect of Bay -75 on PDE1A1 Activity PDE1A1 Activity Bay -75 No Compound Background PDE1A1 Activity Substrate Conc.=nM (camp) IC =.11µM Bay -75, [µm] Page 12 of 36 Client_PDE_Year Month Day 12

13 PDE1B Bay -75 Table Data for the Effect of Bay -75 on PDE1B Activity PDE1B Activity Bay -75 No Compound Background PDE1B Activity Substrate Conc.=nM (camp) IC =.35µM Bay -75, [µm] Page 13 of 36 Client_PDE_Year Month Day 13

14 PDE1C Bay -75 Table Data for the Effect of Bay -75 on PDE1C Activity PDE1C Activity Bay -75 No Compound Background 22 PDE1C Activity Substrate Conc.=nM (camp) IC =.43µM Bay -75, [µm] Page 14 of 36 Client_PDE_Year Month Day 14

15 PDE2A Bay -75 Table Data for the Effect of Bay -75 on PDE2A1 Activity PDE2A1 Activity Bay -75 No Compound Background PDE2A1 Activity Substrate Conc.=nM (camp) Bay -75, [µm] IC =.69µM Page 15 of 36 Client_PDE_Year Month Day 15

16 PDE3A Cilostamide Table Data for the Effect of Cilostamide on PDE3A Activity PDE3A Activity Cilostamide No Compound Background PDE3A Activity Substrate Conc.=nM (camp) IC =.17µM Cilostamide, [µm] Page 16 of 36 Client_PDE_Year Month Day 16

17 PDE3B Cilostamide Table Data for the Effect of Cilostamide on PDE3B Activity PDE3B Activity Cilostamide No Compound Background PDE3B Activity Substrate Conc.=nM (camp) IC =.83µM Cilostamide, [µm] Page 17 of 36 Client_PDE_Year Month Day 17

18 PDE4A1A Rolipram Table Data for the Effect of Rolipram on PDE4A1A Activity PDE4A1A Activity Rolipram No Compound Background PDE4A1A Activity Substrate Conc.=nM (camp) IC =.18µM Rolipram, [µm] Page 18 of 36 Client_PDE_Year Month Day 18

19 PDE4A4B Rolipram Table Data for the Effect of Rolipram on PDE4A4B Activity PDE4A4B Activity Rolipram No Compound Background PDE4A4B Activity Substrate Conc.=nM (camp) IC =.14µM Rolipram, [µm] Page 19 of 36 Client_PDE_Year Month Day 19

20 PDE4A Rolipram Table Data for the Effect of Rolipram on PDE4A Activity PDEA Activity Rolipram No Compound Background PDE4A Activity Substrate Conc.=nM (camp) IC =.16µM Rolipram, [µm] Page of 36 Client_PDE_Year Month Day

21 3.2.. PDE4B Rolipram Table Data for the Effect of Rolipram on PDE4B1 Activity PDE4B1 Activity Rolipram No Compound Background PDE4B1 Activity Substrate Conc.=nM (camp) IC =.12µM Rolipram, [µm] Page 21 of 36 Client_PDE_Year Month Day 21

22 PDE4B Rolipram Table Data for the Effect of Rolipram on PDE4B2 Activity PDE4B2 Activity Rolipram No Compound Background PDE4B2 Activity Substrate Conc.=nM (camp) IC =.11µM Rolipram, [µm] Page 22 of 36 Client_PDE_Year Month Day 22

23 PDE4C Rolipram Table Data for the Effect of Rolipram on PDE4C1 Activity PDE4C1 Activity Rolipram No Compound Background PDE4C1 Activity Substrate Conc.=nM (camp) IC =.24µM Rolipram, [µm] Page 23 of 36 Client_PDE_Year Month Day 23

24 PDE4D Rolipram Table Data for the Effect of Rolipram on PDE4D2 Activity PDE4D2 Activity Rolipram No Compound Background PDE4D2 Activity Substrate Conc.=nM (camp) IC =.12µM Rolipram, [µm] Page 24 of 36 Client_PDE_Year Month Day 24

25 PDE4D Rolipram Table Data for the Effect of Rolipram on PDE4D3 Activity PDE4D3 Activity Rolipram No Compound Background PDE4D3 Activity Substrate Conc.=nM (camp) IC =.11µM Rolipram, [µm] Page 25 of 36 Client_PDE_Year Month Day 25

26 PDE4D Rolipram Table Data for the Effect of Rolipram on PDE4D7 Activity PDE4D7 Activity Rolipram No Compound Background PDE4D7 Activity Substrate Conc.=nM (camp) IC =.12µM Rolipram, [µm] Page 26 of 36 Client_PDE_Year Month Day 26

27 PDE5A Sildenafil Citrate Table Data for the Effect of Sildenafil Citrate on PDE5A1 Activity PDE5A1 Activity Sildenafil Citrate No Compound Background 21 1 PDE5A1 Activity Substrate Conc.=nM (cgmp) IC =.46µM Sildenafil Citrate, [µm] Page 27 of 36 Client_PDE_Year Month Day 27

28 PDE6C Sildenafil Citrate Table Data for the Effect of Sildenafil Citrate on PDE6C Activity PDE6C Activity Sildenafil Citrate No Compound Background PDE6C Activity Substrate Conc.=nM (cgmp) IC =.12µM Sildenafil Citrate, [µm] Page 28 of 36 Client_PDE_Year Month Day 28

29 PDE7A BRL-481 Table Data for the Effect of BRL-481 on PDE7A1 Activity PDE7A1 Activity BRL-481 No Compound Background PDE7A1 Activity Substrate Conc.=nM (camp) 1 IC = 2.1µM BRL-481, [µm] Page 29 of 36 Client_PDE_Year Month Day 29

30 PDE7B Dipyridamole Table Data for the Effect of Dipyridamole on PDE7B Activity PDE7B Activity Dipyridamole No Compound Background PDE7B Activity Substrate Conc.=nM (camp) 1 IC = 4.7µM Dipyridamole, [µm] Page of 36 Client_PDE_Year Month Day

31 3.2.. PDE8A Dipyridamole Table Data for the Effect of Dipyridamole on PDE8A1 Activity PDE8A1 Activity Dipyridamole No Compound Background PDE8A1 Activity Substrate Conc.=nM (camp) 1 IC = 7.7µM Dipyridamole, [µm] Page 31 of 36 Client_PDE_Year Month Day 31

32 PDE9A Bay Table Data for the Effect of Bay on PDE9A2 Activity PDE9A2 Activity Bay No Compound Background PDE9A2 Activity Substrate Conc.=nM (cgmp) IC =.21µM Bay , [µm] Page 32 of 36 Client_PDE_Year Month Day 32

33 PDEA Papaverine Table Data for the Effect of Papaverine on PDEA1 Activity PDEA1 Activity Papaverine No Compound Background PDEA1 Activity Substrate Conc.=nM (camp) IC =.95µM Papaverine, [µm] Page 33 of 36 Client_PDE_Year Month Day 33

34 PDEA Papaverine Table Data for the Effect of Papaverine on PDEA2 Activity PDEA2 Activity Papaverine No Compound Background PDEA2 Activity Substrate Conc.=nM (camp) IC =.64µM Papaverine, [µm] Page 34 of 36 Client_PDE_Year Month Day 34

35 PDE11A Dipyridamole Table Data for the Effect of Dipyridamole on PDE11A4 Activity PDE11A4 Activity Dipyridamole No Compound Background PDE11A4 Activity Substrate Conc.=nM (camp) IC =.45µM Dipyridamole, [µm] Page 35 of 36 Client_PDE_Year Month Day 35

36 4. Quality Assurance Statement I certify that the results presented in this report were generated using the materials and methods mentioned and that these results reflect the Raw Data. Henry Zhu, Ph.D. President Date Page 36 of 36 Client_PDE_Year Month Day 36